Our Proprietary Cellular Immunotherapy Platforms
With intelligent engineering, we are developing next-generation induced Pluripotent Stem Cell (iPSC)-derived natural killer (iNK) cells and macrophages (iMACs) to lead the fight against cancer.
Our platforms are built on a deep understanding of iPSC differentiation, immune cell biology and genetic engineering that enable the development of iNK cells and iMACs as allogeneic “off-the-shelf” cellular immunotherapies designed for durability, scalability, safety and efficacy. Our iPSC approach enables multiplex editing and results in products that are clonal in nature and therefore homogenous and well characterized, properties that we believe will enable an efficient approach to manufacturing.
Our iPSC-based approach creates a modular system whereby each program can serve as a foundation for further gene editing, which we believe enables the development of a robust pipeline. These edits have the potential to convey additional unique benefits to further optimize the therapeutic profile of our cellular immunotherapies.